Madrid, 11 December 2017. The biotechnology companies Biofabri and Probisearch, members of the group formed by Biofabri and CZ Veterinaria, reached an agreement last October with Casen Recordati, the Spanish subsidiary of the Italian pharmaceutical company Recordati, for the clinical and industrial development and subsequent production of two innovative probiotics in the field of Pediatrics and women’s health.
By signing this agreement, Biofabri and Probisearch make progress in the growth strategy they have implemented over the last few years through their new business line which specializes in the development and production of probiotics under pharmaceutical standards. On the other hand, Casen Recordati strengthens its position as a leader in the probiotics field.
ProbiSearch, based in Tres Cantos (Madrid), is a leading company in probiotics research that was founded in 2011 and purchased by the CZ veterinaria-Biofabri group at the end of 2016. Its technical team has worked hard to identify and select more than 50 potentially probiotic bacterial strains for their application in human and animal healthcare. The clinical development of the aforementioned strains is conducted by Probisearch in accordance with the Good Clinical Practice guidelines and in cooperation with private and public health centers.
Pharmaceutical laboratory Biofabri, specialized in biotechnology and based in Porriño (Vigo), has a new separate area that focuses exclusively on the manufacturing of probiotics under the highest technological and pharmaceutical quality standards and is also equipped with environmental control systems to ensure the stability of products and avoid cross-contamination. Thanks to a highly qualified and experienced staff, Biofabri takes into consideration the entire value chain when developing its probiotics, from the first development stages to the final products ready to be put on the market.
Casen Recordati is the Spanish subsidiary of the Recordati pharmaceutical group based in Milan, Italy. It is a European pharmaceutical group open to collaboration and specialized in the discovery, development and marketing of innovative and high value-added products whose goal is to improve people’s quality of life.
In Spain, Casen Recordati has its operations center in Zaragoza and its main place of business in Madrid. It has its own manufacturing plant and research department for the development of new products. As a result, they can produce prescription drugs and self-care products for different diseases and symptoms, thanks to the experience gained through decades of research and close collaboration with healthcare professionals and patients.
The main therapeutic fields where its products are sold include: cardiology, gastroenterology, gynecology, pediatrics and urology. It took a leading role in the probiotics market by launching Casenfilus in 2002, followed by Bi-OralSuero in 2004, Casenbiotic/Reuteri-Biogaia in 2007, Muvagyn probiotic in 2010 and lastly Gastrus in 2016.